Equities analysts forecast that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will post ($0.06) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Catalyst Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.08) and the highest is ($0.05). Catalyst Pharmaceuticals also reported earnings of ($0.06) per share in the same quarter last year. The company is expected to issue its next quarterly earnings results on Tuesday, August 8th.
On average, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.22). For the next fiscal year, analysts expect that the business will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.33) to ($0.15). Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06).
CPRX has been the topic of a number of research analyst reports. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Monday, May 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a report on Monday, March 20th. Finally, Roth Capital set a $3.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 20th.
Several large investors have recently added to or reduced their stakes in the stock. Oxford Asset Management increased its stake in Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 34,181 shares during the period. Bank of New York Mellon Corp increased its stake in Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares during the period. JPMorgan Chase & Co. purchased a new stake in Catalyst Pharmaceuticals during the first quarter valued at $155,000. Berson & Corrado Investment Advisors LLC increased its stake in Catalyst Pharmaceuticals by 31.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 251,025 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 60,425 shares during the period. Finally, Knott David M purchased a new stake in Catalyst Pharmaceuticals during the first quarter valued at $554,000. 30.23% of the stock is currently owned by institutional investors.
Catalyst Pharmaceuticals (NASDAQ:CPRX) opened at 2.77 on Wednesday. The firm’s market cap is $232.09 million. Catalyst Pharmaceuticals has a 1-year low of $0.68 and a 1-year high of $2.88. The firm has a 50-day moving average price of $2.33 and a 200-day moving average price of $1.62.
COPYRIGHT VIOLATION NOTICE: “Catalyst Pharmaceuticals, Inc. (CPRX) Expected to Announce Earnings of -$0.06 Per Share” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/07/30/catalyst-pharmaceuticals-inc-cprx-expected-to-announce-earnings-of-0-06-per-share-updated-updated-updated.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.